Novo Nordisk A/S (NYSE:NVO) Trading 1.4% Higher – Here’s What Happened

Novo Nordisk A/S (NYSE:NVO)’s share price traded up 1.4% on Thursday . The company traded as high as $39.12 and last traded at $39.02. 20,715,432 shares were traded during trading, a decline of 23% from the average session volume of 26,842,309 shares. The stock had previously closed at $38.50.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised Novo Nordisk to Equal Weight, and related analyst chatter lifted the stock in earlier trading — a near-term supportive catalyst. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Neutral Sentiment: General coverage and “trending” write-ups (Zacks/Yahoo) are driving retail attention but contain no new fundamental news; these pieces can increase volume/volatility without changing long?term fundamentals. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Be aware of ticker-noise: several press releases referencing “NVO” (Novo Resources, ASX: NVO) circulated today — these are not related to Novo Nordisk (NYSE:NVO) but can create confusion in scanners and newsfeeds. Completion of Tranche 1 of Placement and Valuation Update
• Negative Sentiment: Roche reported positive Phase II results for petrelintide (up to ~10.7% weight loss with good tolerability) and plans further development — new obesity competitors gaining efficacy/tolerability could pressure Novo Nordisk’s market share and growth expectations. Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
• Negative Sentiment: A study reporting generic Ozempic/Wegovy could be produced for under $3/month highlights potential long?term pricing pressure and margin risk if cheaper biosimilars/generics scale globally. That raises erosion risk to high-margin GLP?1 revenues. Generic Ozempic Could Cost Less Than $3 a Month, Study Shows
• Negative Sentiment: Regulatory scrutiny increased after the FDA issued (another) warning about marketing/ads for Ozempic/Wegovy — ongoing ad/regulatory issues could hurt promotion and patient uptake and lead to fines or stricter controls. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: Pomerantz law firm announced an investigation into Novo Nordisk investor claims, which can increase legal uncertainty and weigh on sentiment until resolved. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. CICC Research assumed coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price for the company. Finally, TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Five analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $53.93.

Novo Nordisk A/S Stock Down 1.2%

The company’s fifty day simple moving average is $51.41 and its 200 day simple moving average is $52.38. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $172.35 billion, a PE ratio of 11.12 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 23.63%.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVO. Capital International Investors grew its position in shares of Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after buying an additional 6,092,192 shares during the period. Loomis Sayles & Co. L P lifted its position in Novo Nordisk A/S by 6.0% during the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares during the period. Franklin Resources Inc. boosted its stake in Novo Nordisk A/S by 5.1% during the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after acquiring an additional 717,719 shares in the last quarter. Morgan Stanley boosted its stake in Novo Nordisk A/S by 3.5% during the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after acquiring an additional 428,660 shares in the last quarter. Finally, Folketrygdfondet grew its holdings in Novo Nordisk A/S by 1.2% in the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after purchasing an additional 117,370 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.